Biocon Reshapes Top Management as Biocon Biologics Integration Deepens

The latest update is out from Biocon Limited ( (IN:BIOCON) ).

Biocon’s board has approved a major leadership reshuffle as part of its ongoing integration with Biocon Biologics, including the resignation of CEO and Managing Director Siddharth Mittal, effective March 31, 2026, as he moves to another role within the group. From April 1, 2026, Biocon Biologics CEO Shreehas Pradeep Tambe will assume the role of Biocon’s CEO and Managing Director for a five-year term, subject to shareholder approval.

The company is also overhauling its finance and governance functions, with interim CFO Mukesh Kamath stepping down on March 31, 2026, and Biocon Biologics CFO Kedar Narayan Upadhye taking over as CFO the following day. In parallel, several key roles, including governance, risk and compliance, HR, and technology, are being shifted to leaders from Biocon Biologics, while a slate of existing senior management personnel will cease in their roles, underscoring a deeper structural integration of the two entities and a consolidation of decision-making at the group level.

More about Biocon Limited

Biocon Limited is an India-based biopharmaceutical company headquartered in Bengaluru, focused on developing and manufacturing biologics, biosimilars, and specialty pharmaceuticals for global markets. Through its subsidiary Biocon Biologics, the group has been integrating operations to position itself as a unified global biopharmaceutical leader with a strong emphasis on innovation, biosimilar therapies, and international expansion.

Average Trading Volume: 171,147

Technical Sentiment Signal: Buy

Current Market Cap: 614.9B INR

See more data about BIOCON stock on TipRanks’ Stock Analysis page.